Cardiovascular Performance Summary Measure Q4 2022 Q4 2021 Change Y/Y ($ in millions) Reported Net Sales $2,005M $1,884M +6.4% Operating Income* % 25.9% 22.2% +400 bps * Represents operating income as a percentage of operational net sales, both excluding the impact of foreign currency, which is a non-GAAP measure. Q4 + FY 2022 Highlights • Cardiology: Q4:22 Global net sales +7.5% as reported, +13.2% operational*, +9.6% organic*'; FY:22 Global net sales +9.4% as reported, +14.5% operational*, +10.4% organic* ◦ Interventional Cardiology: Q4:22 Global net sales -2.4% as reported, +5.2% operational*/organic*; FY:22 Global net sales +0.9% as reported, +7.5% operational*/organic* ▪ Coronary Therapies franchise grew 7%, with strong performance in international regions and Imaging franchise. ▪ The Structural Heart Valves franchise grew double digits in Q4 and FY:22, outpacing the market in Europe with ACURATE Neo2™. ◦ Watchman: Q4:22 Global net sales +20.5% as reported, +21.9% operational*/organic*; FY:22 Global net sales +22.9% as reported, +24.0% operational*/organic* ▪ Q4 finished with record sales and strong utilization in the U.S., supported by DAPT label expansion. ◦ Cardiac Rhythm Management: Q4:22 Global net sales +1.3% as reported, +5.8% operational*/organic*; FY:22 Global net sales +4.0% as reported, +8.3% operational*, +6.7% organic* ▪ Double digit, full year growth versus 2021 in the Diagnostics franchise driven by differentiated and broad portfolio. ▪ In Core CRM, our high-voltage franchise grew low-single digits, and low-voltage franchise grew mid-single digits on a full year basis. ◦ Electrophysiology: Q4:22 Global net sales +66.7% as reported, +76.4% operational*, +25.1% organic*; FY:22 +60.2% as reported, +68.9% operational*, +17.8% organic* ▪ OUS EP business continues to outpace the market, growing 40% organically in Q4 versus 2021, supported by strength in POLARx™ and Farapulse™. ▪ The Baylis acquisition continues to perform well, with the innovative VersaCross Transseptal Access Platform growing 2 times faster than the market in 2022. • Peripheral Interventions: Q4:22 Global net sales +3.0% as reported, +8.8% operational*/organic*; FY:22 Global net sales +4.4% as reported, +9.1% operational*/organic* ◦ Our Drug-Eluting portfolio grew strong double digits in 2022 and achieved the #1 position within the Superficial femoral artery (SFA) in the U.S. ◦ Interventional Oncology franchise grew low-double digits; led by our portfolio of innovative cancer therapies and our suite of embolization tools. ◦ Varithena™ grew over 20% in 2022, gaining share with its innovative approach to treating venous insufficiency. 6 Q4 2022 Financial & Operational Highlights | February 1, 2023